Europe Biosimulation Market Size & Outlook, 2026-2033
The biosimulation market in Europe is expected to reach a projected revenue of US$ 3,950.1 million by 2033. A compound annual growth rate of 15.9% is expected of Europe biosimulation market from 2026 to 2033.
The Europe biosimulation market generated a revenue of USD 1,211.3 million in 2025.
The market is expected to grow at a CAGR of 15.9% from 2026 to 2033.
In terms of segment, software was the largest revenue generating product in 2025.
Services is the most lucrative product segment registering the fastest growth during the forecast period.
Country-wise, France is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
Market revenue in 2025
USD 1,211.3 million
Market revenue in 2033
USD 3,950.1 million
Growth rate
15.9% (CAGR from 2026 to 2033)
Largest segment
Software
Fastest growing segment
Services
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Software, Services
Key market players worldwide
Certara Inc Ordinary Shares, Dassault Systemes SE, Avantium NV, Simulations Plus Inc, Schrodinger Inc Ordinary Shares, Chemical Computing Group, Physiomics, Rosa & Co, Genedata AG, Instem, Yokogawa Electric Corp., Immunetrics
Other key industry trends
In terms of revenue, Europe region accounted for 29.3% of the global biosimulation market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 3,743.0 million by 2033.
The Europe biosimulation market is expected to grow at a significant rate owing to growing need for high potency and efficacious drugs, leading to increase in the adoption of biosimulation software in European countries. Europe hosts various conferences that aim to bring professionals under one roof and spread awareness about the ongoing developments in biosimulation.
The BBSRC and European Molecular Biology Laboratory’s European Institute (EMBL-EBI), with support from the UK government, made a commitment of approximately USD 93 million for ELIXIR research infrastructure. ELIXIR is a pan European institute and is considered as the hub for bioinformatics and computational biology in Europe.
Significant financial contributions have been made toward the construction of ELIXIR nodes throughout Europe by Finland, Denmark, Spain, Norway, Switzerland, and Sweden. The operational costs of these hubs are expected to be met by pooled contributions from member countries.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biosimulation Market Outlook will help companies and investors design strategic landscapes.
Software was the largest segment with a revenue share of 68.88% in 2025.
Horizon Databook has segmented the Europe biosimulation market based on software, services covering the revenue growth of each sub-segment from 2021 to 2033.
The Europe biosimulation market is expected to grow at a significant rate owing to growing need for high potency and efficacious drugs, leading to increase in the adoption of biosimulation software in European countries. Europe hosts various conferences that aim to bring professionals under one roof and spread awareness about the ongoing developments in biosimulation.
The BBSRC and European Molecular Biology Laboratory’s European Institute (EMBL-EBI), with support from the UK government, made a commitment of approximately USD 93 million for ELIXIR research infrastructure. ELIXIR is a pan European institute and is considered as the hub for bioinformatics and computational biology in Europe.
Significant financial contributions have been made toward the construction of ELIXIR nodes throughout Europe by Finland, Denmark, Spain, Norway, Switzerland, and Sweden. The operational costs of these hubs are expected to be met by pooled contributions from member countries.
Europe Biosimulation Market Product Outlook (Revenue, USD Million , 2021-2033)
Software
Services
Reasons to subscribe to Biosimulation Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biosimulation Market Outlook databook
Our clientele includes a mix of Biosimulation Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Biosimulation Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Biosimulation Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.